BioMarin Pharmaceutical, Inc. (BMRN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151217,
    "name": "BioMarin Pharmaceutical, Inc.",
    "stock_name": "BioMarin Pharmaceutical, Inc.",
    "full_name": "BioMarin Pharmaceutical, Inc.",
    "name_url": "stocks-analysis/biomarin-pharmaceutical-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "53.82",
    "chg": -0.07,
    "chgp": "-0.13%",
    "dir": -1,
    "prev_price": "53.89",
    "mcapval": "10,825.78",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09061G1013",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.77 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/biomarin-pharmaceutical-inc-1151217-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-overvalued-or-undervalued-3637634",
        "imagepath": "",
        "date": "2025-10-21 12:06:06",
        "description": "As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. moved from very attractive to fair. The company appears to be fairly valued given its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth relative to its price.\n\nIn comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting it is more attractively priced within its industry. Despite this, the company has underperformed significantly against the S&P 500, with a year-to-date return of -18.93% compared to the index's 13.30%. This trend continues over longer periods, with a three-year return of -39.98% versus the S&P 500's 81.19%, reinforcing the notion that while the stock may be fairly valued, it faces challenges in delivering returns...."
      },
      {
        "title": "BioMarin Pharmaceutical, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/biomarin-pharmaceuticals-valuation-grade-downgraded-from-very-attractive-to-fair-3640539",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioMarinPharmac_valuationdot_3640539.png",
        "date": "2025-10-20 15:37:00",
        "description": "BioMarin Pharmaceutical, Inc. has recently adjusted its valuation, reflecting a reassessment of its financial metrics within the pharmaceuticals and biotechnology sector. The company shows competitive valuation ratios compared to peers, although its stock performance has faced challenges, with notable declines over the past year."
      },
      {
        "title": "Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-overvalued-or-undervalued-3634501",
        "imagepath": "",
        "date": "2025-10-20 12:23:36",
        "description": "As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth at a reasonable price.\n\nIn comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting that BioMarin may offer better value relative to these competitors. Additionally, Halozyme Therapeutics, Inc. is also rated as fair with a P/E of 15.92, further supporting the notion that BioMarin is competitively positioned within its industry. Although specific return data is not available, the lack of negative performance relative to the S&P 500 reinforces the company's stable valuation outlook...."
      },
      {
        "title": "Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-overvalued-or-undervalued-3632039",
        "imagepath": "",
        "date": "2025-10-19 12:01:07",
        "description": "As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth relative to its price.\n\nIn comparison to peers, BioMarin's P/E ratio is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, both of which are considered expensive. Additionally, Halozyme Therapeutics, Inc. is also rated fair with a P/E of 15.92, suggesting that BioMarin is competitively positioned within its peer group. However, the company's returns have significantly lagged behind the S&P 500, with a year-to-date return of -18.93% compared to the index's 13.30%, highlighting a challenging performance landscape...."
      },
      {
        "title": "BioMarin Pharmaceutical Hits 52-Week Low at USD 51.56 Amid Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/biomarin-pharmaceutical-hits-52-week-low-at-usd-5156-amid-decline-3622763",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioMarinPharmac_priceRelatedfactors_3622763.png",
        "date": "2025-10-15 16:50:24",
        "description": "BioMarin Pharmaceutical, Inc. has reached a new 52-week low, trading at USD 51.56. The company has experienced a significant stock price decline over the past year, with a market capitalization of approximately USD 10.83 billion. Key financial metrics include a P/E ratio of 20.00 and a return on equity of 11.84%."
      },
      {
        "title": "BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/biomarin-pharmaceuticals-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-fluctuations-3600882",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BioMarinPharmac_technicaldot_3600882.png",
        "date": "2025-10-07 19:24:20",
        "description": "BioMarin Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has seen a slight increase, but the company has struggled over the past year and three years, significantly underperforming compared to the S&P 500, indicating the need for strategic adjustments."
      },
      {
        "title": "Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-technically-bullish-or-bearish-3599017",
        "imagepath": "",
        "date": "2025-10-07 12:16:12",
        "description": "As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a mildly bearish trend in both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. The Dow Theory suggests a mildly bullish trend weekly, with no trend monthly.\n\nIn terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -15.40% compared to the S&P 500's 14.18%, and a one-year return of -20.00% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, reflecting mixed signals across different indicators...."
      },
      {
        "title": "Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-technically-bullish-or-bearish-3593740",
        "imagepath": "",
        "date": "2025-10-06 12:06:14",
        "description": "As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bearish stance on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but bearish monthly. The Dow Theory indicates a mildly bearish trend weekly with no trend monthly. The OBV is mildly bullish weekly but shows no trend monthly.\n\nIn terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.67% compared to the S&P 500's 14.18%, and a one-year return of -18.68% versus 17.82% for the index. Overall, the current technical stance is mildly bearish...."
      },
      {
        "title": "Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biomarin-pharmaceutical-inc-technically-bullish-or-bearish-3591810",
        "imagepath": "",
        "date": "2025-10-05 11:51:09",
        "description": "As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bearish stance for both weekly and monthly periods. Daily moving averages are bearish, and the KST shows a mildly bullish signal on the weekly but bearish on the monthly. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. The OBV is mildly bullish on the weekly timeframe. \n\nIn terms of performance, BioMarin has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.67% compared to the S&P 500's 14.18%, and a one-year return of -18.68% versus the S&P 500's 17.82%. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and mixed signals from MACD a..."
      }
    ],
    "total": 17,
    "sid": "1151217",
    "stock_news_url": "https://www.marketsmojo.com/news/biomarin-pharmaceutical-inc-1151217"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?

2025-10-21 12:06:06

As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. moved from very attractive to fair. The company appears to be fairly valued given its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth relative to its price. In comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting it is more attractively priced within its industry. Despite this, the company has underperformed significantly against the S&P 500, with a year-to-date return of -18.93% compared to the index's 13.30%. This trend continues over longer periods, with a three-year return of -39.98% versus the S&P 500's 81.19%, reinforcing the notion that while the stock may be fairly valued, it faces challenges in delivering returns....

BioMarin Pharmaceutical, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-20 15:37:00

BioMarin Pharmaceutical, Inc. has recently adjusted its valuation, reflecting a reassessment of its financial metrics within the pharmaceuticals and biotechnology sector. The company shows competitive valuation ratios compared to peers, although its stock performance has faced challenges, with notable declines over the past year.

Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?

2025-10-20 12:23:36

As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. has moved from very attractive to fair. The company appears to be fairly valued based on its current metrics. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth at a reasonable price. In comparison to its peers, BioMarin's P/E ratio of 15.17 is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, suggesting that BioMarin may offer better value relative to these competitors. Additionally, Halozyme Therapeutics, Inc. is also rated as fair with a P/E of 15.92, further supporting the notion that BioMarin is competitively positioned within its industry. Although specific return data is not available, the lack of negative performance relative to the S&P 500 reinforces the company's stable valuation outlook....

Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?

2025-10-19 12:01:07

As of 17 October 2025, the valuation grade for BioMarin Pharmaceutical, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 20, while the EV to EBITDA ratio is 14.21, and the PEG ratio is notably low at 0.14, indicating potential growth relative to its price. In comparison to peers, BioMarin's P/E ratio is lower than Illumina, Inc. at 19.09 and Elanco Animal Health, Inc. at 19.25, both of which are considered expensive. Additionally, Halozyme Therapeutics, Inc. is also rated fair with a P/E of 15.92, suggesting that BioMarin is competitively positioned within its peer group. However, the company's returns have significantly lagged behind the S&P 500, with a year-to-date return of -18.93% compared to the index's 13.30%, highlighting a challenging performance landscape....

BioMarin Pharmaceutical Hits 52-Week Low at USD 51.56 Amid Decline

2025-10-15 16:50:24

BioMarin Pharmaceutical, Inc. has reached a new 52-week low, trading at USD 51.56. The company has experienced a significant stock price decline over the past year, with a market capitalization of approximately USD 10.83 billion. Key financial metrics include a P/E ratio of 20.00 and a return on equity of 11.84%.

BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-07 19:24:20

BioMarin Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has seen a slight increase, but the company has struggled over the past year and three years, significantly underperforming compared to the S&P 500, indicating the need for strategic adjustments.

Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?

2025-10-07 12:16:12

As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a mildly bearish trend in both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. The Dow Theory suggests a mildly bullish trend weekly, with no trend monthly. In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -15.40% compared to the S&P 500's 14.18%, and a one-year return of -20.00% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, reflecting mixed signals across different indicators....

Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?

2025-10-06 12:06:14

As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bearish stance on both weekly and monthly time frames. Daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but bearish monthly. The Dow Theory indicates a mildly bearish trend weekly with no trend monthly. The OBV is mildly bullish weekly but shows no trend monthly. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.67% compared to the S&P 500's 14.18%, and a one-year return of -18.68% versus 17.82% for the index. Overall, the current technical stance is mildly bearish....

Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?

2025-10-05 11:51:09

As of 3 October 2025, the technical trend for BioMarin Pharmaceutical, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a mildly bearish stance for both weekly and monthly periods. Daily moving averages are bearish, and the KST shows a mildly bullish signal on the weekly but bearish on the monthly. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. The OBV is mildly bullish on the weekly timeframe. In terms of performance, BioMarin has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.67% compared to the S&P 500's 14.18%, and a one-year return of -18.68% versus the S&P 500's 17.82%. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and mixed signals from MACD a...

View All News